首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1459609

全球生物製品市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Biologics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年03月01日 | 出版商:

Value Market Research | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球生物製劑市場需求預計將從 2023 年的 5,530.9 億美元達到近 10,288.7 億美元的市場規模，2024-2032 年研究期間CAGR為 7.14%。

生物製品是源自活生物體或其成分的藥物，包括蛋白質、核酸、碳水化合物或細胞。與化學合成的小分子傳統藥物不同，生物製劑是利用重組 DNA 技術、細胞培養或微生物發酵等生物技術製程生產的。生物製劑包括各種治療劑，包括單株抗體、細胞激素、荷爾蒙、酵素、疫苗和基因療法，用於治療多種疾病，如癌症、自體免疫疾病、傳染病和遺傳性疾病。

市場動態

癌症、自體免疫疾病和代謝疾病等慢性疾病的盛行率不斷上升，推動了市場對提供針對性和個人化治療選擇的生物療法的需求。生物製劑是從細胞、組織、蛋白質等生物體中提取的大分子藥物，與傳統小分子藥物相比，具有特異性更高、副作用減少、療效提高等優點。此外，生物技術、基因組學和免疫學的進步推動了生物藥物發現、開發和製造流程的創新，使製造商能夠開發新的生物療法來滿足未滿足的醫療需求。此外，監管機構、醫療保健提供者和患者對生物製劑的接受度不斷提高，加上報銷範圍和市場准入的不斷擴大，正在加速生物製劑治療在腫瘤學、風濕病學、皮膚病學和胃腸病學等各治療領域的市場採用。此外，在醫療保健支出增加、中產階級人口擴大和醫療保健服務可及性改善的推動下，新興經濟體不斷擴大的市場機會正在刺激對生物製劑的需求，作為國家醫療保健政策和全民健康覆蓋舉措的一部分。此外，製藥公司、生技新創公司和學術機構不斷增加研發投資，以發現和開發新型生物療法，包括單株抗體、重組蛋白和細胞療法，正在推動市場創新和成長。此外，在基因組定序、生物標記識別和患者分層的進步推動下，個人化醫療和精準醫療保健的不斷成長趨勢正在為針對個別患者概況和疾病特徵量身定做的標靶生物療法創造市場機會。然而，高生產成本、監管障礙以及生物相似藥產品的競爭可能會阻礙市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球生物製品市場的各個細分市場進行了包容性評估。生物製品產業的成長和趨勢為本研究提供了整體方法。

市場區隔

生物製劑市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按產品分類

單株抗體
重組蛋白
疫苗
細胞與基因治療
其他

按申請

腫瘤學
自體免疫和免疫疾病
血液系統疾病
傳染性疾病
其他（心血管疾病等）

按製造

外包
內部

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲生物製品市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。生物製劑市場的主要參與者包括艾伯維、安進、阿斯特捷利康、百時美施貴寶公司、禮來公司、吉利德科學公司、葛蘭素史克、強生服務公司、默克公司、諾華公司、輝瑞公司Inc.，F.霍夫曼-拉羅氏股份公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：生物製品公司的競爭格局

生物製品市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
AbbVie

公司簡介
公司收入
產品
最近的發展

Amgen

公司簡介
公司收入
產品
最近的發展

AstraZeneca

公司簡介
公司收入
產品
最近的發展

Bristol-Myers Squibb Company

公司簡介
公司收入
產品
最近的發展

Eli Lilly

公司簡介
公司收入
產品
最近的發展

Gilead Sciences Inc.

公司簡介
公司收入
產品
最近的發展

GlaxoSmithKline

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson Services Inc.

公司簡介
公司收入
產品
最近的發展

Merck & Co. Inc.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche AG

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112114075

The global demand for Biologics Market is presumed to reach the market size of nearly USD 1028.87 Billion by 2032 from USD 553.09 Billion in 2023 with a CAGR of 7.14% under the study period 2024 - 2032.

Biologics are pharmaceutical drugs derived from living organisms or their components, including proteins, nucleic acids, carbohydrates, or cells. Unlike small-molecule traditional medicines chemically synthesized, biologics are produced using biotechnological processes such as recombinant DNA technology, cell culture, or microbial fermentation. Biologics encompass various therapeutic agents, including monoclonal antibodies, cytokines, hormones, enzymes, vaccines, and gene therapies, used to address multiple medical conditions such as cancer, autoimmune diseases, infectious diseases, and genetic disorders.

MARKET DYNAMICS

The escalating prevalence of chronic diseases like cancer, autoimmune disorders, and metabolic diseases is driving market demand for biological therapies that offer targeted and personalized treatment options. Biologics are large molecule drugs derived from living organisms such as cells, tissues, and proteins, offering advantages such as higher specificity, reduced side effects, and improved efficacy compared to traditional small molecule drugs. Additionally, biotechnology, genomics, and immunology advancements propel innovation in biologic drug discovery, development, and manufacturing processes, enabling manufacturers to develop novel biologic therapies for unmet medical needs. Moreover, the growing acceptance of biologics by regulatory agencies, healthcare providers, and patients, coupled with increasing reimbursement coverage and market access, is accelerating the market adoption of biologic treatments in various therapeutic areas such as oncology, rheumatology, dermatology, and gastroenterology. Furthermore, the expanding market opportunities in emerging economies, driven by rising healthcare expenditures, expanding middle-class populations, and improving access to healthcare services, are stimulating demand for biologics as part of national healthcare policies and universal health coverage initiatives. Additionally, the increasing investments in research and development by pharmaceutical companies, biotechnology startups, and academic institutions to discover and develop novel biologic therapies, including monoclonal antibodies, recombinant proteins, and cell-based therapies, are driving market innovation and growth. Moreover, the growing trend of personalized medicine and precision healthcare, fueled by advances in genomic sequencing, biomarker identification, and patient stratification, is creating market opportunities for targeted biologic therapies tailored to individual patient profiles and disease characteristics. However, high production costs, regulatory hurdles, and competition from biosimilar products may hinder market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of biologics. The growth and trends of biologics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the biologics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Monoclonal Antibodies
Recombinant Proteins
Vaccines
Cell & Gene Therapy
Others

By Application

Oncology
Autoimmune & Immunological Disorders
Hematological Disorders
Infectious Diseases
Others (Cardiovascular Disorders, Etc.)

By Manufacturing

Outsourced
In-House

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Biologics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Biologics market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . BIOLOGICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Manufacturing
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL BIOLOGICS MARKET ANALYSIS BY PRODUCT

5.1 Overview by Product
5.2 Historical and Forecast Data
5.3 Analysis by Product
5.4 Monoclonal Antibodies Historic and Forecast Sales by Regions
5.5 Recombinant Proteins Historic and Forecast Sales by Regions
5.6 Vaccines Historic and Forecast Sales by Regions
5.7 Cell & Gene Therapy Historic and Forecast Sales by Regions
5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL BIOLOGICS MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Oncology Historic and Forecast Sales by Regions
6.5 Autoimmune & Immunological Disorders Historic and Forecast Sales by Regions
6.6 Hematological Disorders Historic and Forecast Sales by Regions
6.7 Infectious Diseases Historic and Forecast Sales by Regions
6.8 Others (Cardiovascular Disorders, etc.) Historic and Forecast Sales by Regions

7 . GLOBAL BIOLOGICS MARKET ANALYSIS BY MANUFACTURING

7.1 Overview by Manufacturing
7.2 Historical and Forecast Data
7.3 Analysis by Manufacturing
7.4 Outsourced Historic and Forecast Sales by Regions
7.5 In-house Historic and Forecast Sales by Regions

8 . GLOBAL BIOLOGICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE BIOLOGICS COMPANIES

9.1. Biologics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF BIOLOGICS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. AbbVie
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Amgen
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. AstraZeneca
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Bristol-Myers Squibb Company
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Eli Lilly
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Gilead Sciences Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. GlaxoSmithKline
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Johnson & Johnson Services Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Merck & Co. Inc.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Novartis AG
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Pfizer Inc.
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
10.14. F. Hoffmann-La Roche AG
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments